Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Mereo BioPharma Group plcNASDAQ: MREO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow shrinks to $0

Q1 FY2026 financing cash flow was $0, compared with $422K a year earlier. Trailing-twelve-month financing cash flow was -$95.27K. Over 3 fiscal years it compounded at +17.8% a year.

Context

  • Financing cash flow amounted to 65.4% of revenue in FY2025.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$23.82K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$327K-99.3% YoY
LTMMar 2026
-$95.27K-100.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-99.3%——
3-year CAGR+17.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
327K USD
Year-over-year change
-99.3%
4-year CAGR
-76.4%

Financing Cash Flow vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.2% is the 8th highest of 10, against a peer median of +3.6%.
  • Financing cash flow amounts to 19.1% of revenue for MREO, versus a peer median of 11.3%.
MREO Competitors
Financing Cash Flow for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$250.31M USD+66.3%+271.0%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$219.24M USD+164739.1%+946.8%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$151.78M USD+62.0%+41.1%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$141.48M USD+10580.1%+128.2%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$112.79M USD+3.6%——
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.63M EUR-102.3%-61.5%12.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.02M CHF-9.0%-10.2%28.5%
IMMPImmutep LimitedFY2025A$525.12K AUD-100.6%—10.4%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$191.89K USD-76.4%-2.7%—
MREOMereo BioPharma Group plcLTM Mar 2026$95.27K USD-100.2%+17.8%19.1%
SLNSilence Therapeutics plcLTM Mar 2026$911.01 USD—-93.4%0.1%
Peer median (excluding MREO) —+3.6%+19.2%11.3%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.